You are here: Industry Insights > Lung

News List

~7 Percent of Lung Transplants Due to COVID-19 Respiratory Failure drugs.com
January 26, 2022
From August 2020 through September 2021, about 7 percent of lung transplantations were performed in patients with COVID-19-related...
Large collaboration creates cell atlas of COVID-19 pathology worldpharmanews
May 08, 2021
Scientists from several hospitals and research centers have shown what happens in individual cells of patients who died of COVID-19. In a study published in Nature, the researchers describe how infected cells from multiple organs exhibited a range of ...
FDA Expands Collaboration with CN Bio to Investigate Lung-On-A-Chip Model for Inhaled Drug Evaluation Applications americanpharmaceuticalreview
May 07, 2021
CN Bio, a developer of single- and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, announced that the U.S. Food and Drug Administration (FDA) has extended their research collaboration ...
COVID-19 survivors may face long-term complications: GlobalData expresspharma
April 14, 2021
Further follow-up on the long-term effects of the disease needs to be conducted, along with treatments to prevent these outcomes.
Windlas Biotech, Mateon Therapeutics partner to launch combined lung therapy and AI telemedicine solution expresspharma
February 23, 2021
The solution consists of three components: the drug PulmoHeal, an AI lung health assessment tool called ArtiHealthand, a post-marketing survey platform.
Fresenius Kabi Recalls Ketorolac Tromethamine Injection americanpharmaceuticalreview
January 15, 2021
Fresenius Kabi USA is voluntarily recalling a single lot of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter.
CN Bio, University of Melbourne collaborate to advance therapies for respiratory complications in recovered Covid-19 patients pharmaceutical-business-review
December 18, 2020
CN Bio announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients.
Ampion Study Advances to 3rd Group of COVID-19 Patients with Respiratory Distress americanpharmaceuticalreview
December 02, 2020
Ampio Pharmaceuticals announced the third group in the Phase I inhaled Ampion™ clinical study is being treated following clearance by the Safety Monitoring Committee (SMC) who found Ampion to be safe and well-tolerated after reviewing the results from ...
Doctors use existing treatment earlier to save the lives of COVID-19 patients worldpharmanews
November 27, 2020
The lives of patients hospitalised with COVID-19 are being saved by doctors who are using an existing medical treatment at an earlier stage.
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease prnasia
November 23, 2020
RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease - a rare condition with no FDA-approved first-line therapy.

Previous page 1 2 3 4 5 6 7 8 9 Next page